EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine

Shu Niu, Khalid A Alkhuzam, Dawei Guan, Tianze Jiao, Lizheng Shi iD, Vivian Fonseca iD, Neda Laiteerapong, Mohammed K Ali, Desmond A Schatz, Jingchuan Guo iD, Hui Shao iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15332 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Shu Niu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Complications, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study compared the 5‐year incidence rate of macrovascular and microvascular complications for tirzepatide, semaglutide and insulin glargine in individuals with type 2 diabetes, using the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes simulation model. Research Design and Methods This study was a 5‐year SURPASS‐2 trial extrapolation, with an insulin glargine arm added as an additional comparator. The 1‐year treatment effects of tirzepatide (5, 10 or 15 mg), semaglutide (1 mg) and insulin glargine on glycated haemoglobin, systolic blood pressure, low‐density lipoprotein and body weights were obtained from the SUSTAIN‐4 and SURPASS‐2 trials. We used the BRAVO model to predict 5‐year complications for each study arm under two scenarios: the 1‐year treatment effects persisted (optimistic) or diminished to none in 5 years (conservative).

Results

When compared with insulin glargine, we projected a 5‐year risk reduction in cardiovascular adverse events [rate ratio (RR) 0.64, 95% confidence interval (CI) 0.61‐0.67] and microvascular composite (RR 0.67, 95% CI 0.64‐0.70) with 15 mg tirzepatide, and 5‐year risk reduction in cardiovascular adverse events (RR 0.75, 95% CI 0.72‐0.79) and microvascular composite (RR 0.79, 95% CI 0.76‐0.82) with semaglutide (1 mg) under an optimistic scenario. Lower doses of tirzepatide also had similar, albeit smaller benefits. Treatment effects for tirzepatide and semaglutide were smaller but still significantly higher than insulin glargine under a conservative scenario. The 5‐year risk reduction in diabetes‐related complication events and mortality for the 15 mg tirzepatide compared with insulin glargine ranged from 49% to 10% under an optimistic scenario, which was reduced by 17%‐33% when a conservative scenario was assumed.

Conclusion

With the use of the BRAVO diabetes model, tirzepatide and semaglutide exhibited potential to reduce the risk of macrovascular and microvascular complications among individuals with type 2 diabetes, compared with insulin glargine in a 5‐year window. Based on the current modelling assumptions, tirzepatide (15 mg) may potentially outperform semaglutide (1 mg). While the BRAVO model offered insights, the long‐term cardiovascular benefit of tirzepatide should be further validated in a prospective clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes ComplicationsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsInsulin GlargineProspective StudiesTirzepatideSemaglutideNitriles

Stichwörter der Autor:innen

cardiovascular diseasediabetes complicationssemaglutidetirzepatidetrial extrapolationtype 2 diabetes

Substanzen

Hypoglycemic AgentsInsulin GlargineTirzepatideSemaglutidetetrachloroisophthalonitrileNitriles

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Center for Drug Evaluation and Safety, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.
  • Biological Sciences Division, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Lizheng Shi, Vivian Fonseca, Jingchuan Guo, Hui Shao

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Niu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V., Laiteerapong, N., Ali, M. K., Schatz, D. A., Guo, J., & Shao, H. (2024). 5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15332

Vancouver

Niu S, Alkhuzam KA, Guan D, Jiao T, Shi L, Fonseca V, et al. 5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15332

BibTeX
@article{Niu2024,
  author = {Niu, Shu and Alkhuzam, Khalid A and Guan, Dawei and Jiao, Tianze and Shi, Lizheng and Fonseca, Vivian and Laiteerapong, Neda and Ali, Mohammed K and Schatz, Desmond A and Guo, Jingchuan and Shao, Hui},
  title = {5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15332}
}
Kostenlos starten →